177 related articles for article (PubMed ID: 33832957)
41. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
Bailey CJ; Gross JL; Hennicken D; Iqbal N; Mansfield TA; List JF
BMC Med; 2013 Feb; 11():43. PubMed ID: 23425012
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
Umpierrez G; Tofé Povedano S; Pérez Manghi F; Shurzinske L; Pechtner V
Diabetes Care; 2014 Aug; 37(8):2168-76. PubMed ID: 24842985
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.
Iwamoto Y; Tajima N; Kadowaki T; Nonaka K; Taniguchi T; Nishii M; Arjona Ferreira JC; Amatruda JM
Diabetes Obes Metab; 2010 Jul; 12(7):613-22. PubMed ID: 20590736
[TBL] [Abstract][Full Text] [Related]
44. Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
Tinahones FJ; Gallwitz B; Nordaby M; Götz S; Maldonado-Lutomirsky M; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2017 Feb; 19(2):266-274. PubMed ID: 27762093
[TBL] [Abstract][Full Text] [Related]
45. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study.
Garber AJ; Bruce S; Fiedorek FT
Clin Ther; 2002 Sep; 24(9):1401-13. PubMed ID: 12380632
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Dandona P; Mathieu C; Phillip M; Hansen L; Griffen SC; Tschöpe D; Thorén F; Xu J; Langkilde AM;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):864-876. PubMed ID: 28919061
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
[TBL] [Abstract][Full Text] [Related]
48. Factors that influence the efficacy of acarbose and metformin as initial therapy in Chinese patients with newly diagnosed type 2 diabetes: a subanalysis of the MARCH trial.
Zhang J; Wang N; Xing X; Yang Z; Wang X; Yang W
Curr Med Res Opin; 2016; 32(4):713-9. PubMed ID: 26714411
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC
Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911
[TBL] [Abstract][Full Text] [Related]
50. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.
Davidson JA; McMorn SO; Waterhouse BR; Cobitz AR
Clin Ther; 2007 Sep; 29(9):1900-14. PubMed ID: 18035190
[TBL] [Abstract][Full Text] [Related]
51. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH; Wolever TM
Ann Intern Med; 1994 Dec; 121(12):928-35. PubMed ID: 7734015
[TBL] [Abstract][Full Text] [Related]
52. Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Weng J; Zeng L; Zhang Y; Qu S; Wang X; Li P; Fu L; Ma B; Ye S; Sun J; Lu W; Liu Z; Chen D; Cheng Z; Liu H; Zhang T; Zou J
Diabetes Obes Metab; 2021 Aug; 23(8):1754-1764. PubMed ID: 33769656
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial.
Chen YH; Huang CN; Cho YM; Li P; Gu L; Wang F; Yang J; Wang WQ
Diabetes Obes Metab; 2018 Sep; 20(9):2121-2130. PubMed ID: 29708650
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
Pratley RE; Kipnes MS; Fleck PR; Wilson C; Mekki Q;
Diabetes Obes Metab; 2009 Feb; 11(2):167-76. PubMed ID: 19125778
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial.
Sone H; Kaneko T; Shiki K; Tachibana Y; Pfarr E; Lee J; Tajima N
Diabetes Obes Metab; 2020 Mar; 22(3):417-426. PubMed ID: 31692244
[TBL] [Abstract][Full Text] [Related]
56. Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial.
Zhu D; Li X; Ma J; Zeng J; Gan S; Dong X; Yang J; Lin X; Cai H; Song W; Li X; Zhang K; Zhang Q; Lu Y; Bu R; Shao H; Wang G; Yuan G; Ran X; Liao L; Zhao W; Li P; Sun L; Shi L; Jiang Z; Xue Y; Jiang H; Li Q; Li Z; Fu M; Liang Z; Guo L; Liu M; Xu C; Li W; Yu X; Qin G; Yang Z; Su B; Zeng L; Geng H; Shi Y; Zhao Y; Zhang Y; Yang W; Chen L
Nat Med; 2022 May; 28(5):965-973. PubMed ID: 35551294
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).
Giorgino F; Benroubi M; Sun JH; Zimmermann AG; Pechtner V
Diabetes Care; 2015 Dec; 38(12):2241-9. PubMed ID: 26089386
[TBL] [Abstract][Full Text] [Related]
58. Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents.
Rosenstock J; Franco D; Korpachev V; Shumel B; Ma Y; Baughman R; Amin N; McGill JB;
Diabetes Care; 2015 Dec; 38(12):2274-81. PubMed ID: 26253730
[TBL] [Abstract][Full Text] [Related]
59. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
[TBL] [Abstract][Full Text] [Related]
60. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study.
Hotta N; Kakuta H; Sano T; Matsumae H; Yamada H; Kitazawa S; Sakamoto N
Diabet Med; 1993 Mar; 10(2):134-8. PubMed ID: 8458189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
